Navigation Links
Researchers discover metabolic vulnerability in TB and potential drug target
Date:5/10/2010

NEW YORK (May 10, 2010) -- Tuberculosis (TB) has been present in humans since ancient times. The origins of the disease date back to the first domestication of cattle, and skeletal remains show prehistoric humans (4,000 B.C.) had TB. Although relatively rare in the United States, it is the single leading bacterial cause of death worldwide. Approximately 8 million people are infected each year and 2 million people die from TB.

The cause of tuberculosis is Mycobacterium tuberculosis (Mtb), a slow-growing aerobic bacterium that divides every 16 to 20 hours. Scientists know that carbon metabolism plays a significant role in the ability of Mtb to replicate and persist in the body and that fatty acids are the major source of carbon and energy during infection. However, the specific enzymes required for the metabolism of fatty acids have not been completely defined.

New research conducted at Weill Cornell Medical College and published online in the Proceedings of the National Academy of Sciences (PNAS) sheds light on a previously unrecognized aspect of fatty acid metabolism that could potentially lead to new targets for drug therapy. A team led by Dr. Sabine Ehrt, professor of microbiology and immunology at Weill Cornell Medical College, reported that Mtb relies primarily on gluconeogenic substrates for in vivo growth and persistence, and that phosphoenolpyruvate carboxykinase (PEPCK) plays a pivotal role in the growth and survival of Mtb during infections in mice, making PEPCK a potential target for drugs that fight tuberculosis.

Dr. Ehrt and her colleagues found a way to silence the gene encoding PEPCK in Mtb during mouse infections to assess the importance of gluconeogenesis for Mtb's ability to maintain a chronic infection. According to Dr. Ehrt, "Silencing a gene when the pathogen is not or only slowly replicating, after an infection has established, is an important tool for studying diseases such as TB, which can be dormant for years only to become active again years later."

Dr. Ehrt, the lead author on the paper, conducts basic research on the pathogenesis of tuberculosis. She and her team investigate the role of the macrophage in the immune response to Mtb and the molecular mechanisms used by the pathogen to establish and maintain persistent infections. A goal of Dr. Ehrt's research is to validate novel drug targets that may facilitate the development of new therapies against active and chronic TB.

"Tuberculosis is very difficult to treat," says Dr. Erht. "It is especially challenging as the infection can lay dormant in the body even though there are no symptoms. We investigated the metabolic requirements of Mtb during acute and chronic infections and found that the gluconeogenic enzyme PEPCK is critical for both."

The study used a novel mass spectrometry-based metabolic profiling tool, developed at Weill Cornell (in collaboration with Agilent Technologies) by Dr. Kyu Rhee to biochemically examine Mtb carbon metabolism. The tool has provided the first direct insights into the metabolic architecture of Mtb. Dr. Rhee is a co-author and assistant professor of medicine, microbiology & immunology, and the Hearst Clinical Scholar in Microbiology & Infectious Diseases at Weill Cornell Medical College.

Dr. Ehrt hopes that her work will eventually lead to new drug therapies to treat tuberculosis. "Although the current treatments we have to treat Mtb are effective, the treatment times are too long and the regimens too complex. This leads to treatment failures, due to poor adherence and multidrug resistance. We need new, safer drugs that work faster to eliminate tuberculosis."


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related biology news :

1. Researchers use entire islands in the Bahamas to test survival of the fittest
2. Researchers discover genetic link between both types of ALS
3. UBC researchers design new biomaterial that mimics muscle elasticity
4. UCLA researchers show how worlds smallest coffee ring may help biosensors detect disease
5. Researchers find melanoma not caused by early UVA light exposure
6. Bugging out: NC State researchers help track wayward pests through mapping
7. Aboriginal hunting and burning increase Australias desert biodiversity, Stanford researchers find
8. Ben-Gurion U researchers isolate microalgal strain that could reduce cholesterol
9. JGH researchers help pinpoint osteoporosis genes
10. Researchers recommend pregnant women take 4,000 IU vitamin D a day
11. Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
(Date:3/9/2016)... Fla. , March 9, 2016  Crossmatch ... authentication and enrollment solutions, today announced the addition ... ® Altus multi-factor authentication platform. New ... InfoSec managers to step-up security where it,s needed ... Washington, DC . --> ...
Breaking Biology News(10 mins):
(Date:5/19/2016)... Columbia , May 19, 2016  AdvancedFlow ... Innovations Inc. (AGI), based out of ... Greenlane Biogas Ltd. to its existing portfolio of ... manufacturing agreement. AFS along with its sister companies ... is a vertically integrated industrial group that specializes ...
(Date:5/18/2016)... ... May 18, 2016 , ... Tech Coast Angels ... Villalobos Award to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia. ... financed by one of ACA’s member angel groups. It is the highest honor available ...
(Date:5/18/2016)... IN (PRWEB) , ... May 18, 2016 , ... The ... and is now celebrating its dream of reaching a total of $1 million in ... scholarships awarded to 10 high school graduates from across the nation has helped bring ...
(Date:5/17/2016)... (PRWEB) , ... May 17, 2016 , ... ... Deliver Global Conference that they will collaborate to bring a feeding cup to ... School of Dentistry, and the Craniofacial Center at Seattle Children’s Hospital, thereby ensuring ...
Breaking Biology Technology: